January 25, 2021

Dusan Kosijer apppointed CEO of Minaris Regenerative Medicine GmbH

MUNICH, Germany – January 25, 2021- Minaris Regenerative Medicine GmbH, a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry fully owned by Showa Denko Materials Co., Ltd., announces the appointment of Dusan Kosijer as CEO of the European operations of Minaris as of January 1, 2021.

Dusan Kosijer has served as Chief Financial Officer of Minaris Regenerative Medicine GmbH since 2016 and was instrumental in driving growth and profitability for the organization. In 2020, he also accepted a global role as Global Chief Financial Officer for the Regenerative Medicine Business Sector of Showa Denko Materials Co., Ltd. Previously, he was CFO for a Contract Research Organization headquartered close to Frankfurt, Germany. He is a Certified Management Accountant by training and has more than 20 years’ experience in the healthcare sector.Dusan-Kosijer

Dusan Kosijer, CEO of Minaris Regenerative Medicine GmbH

“We are very happy that Dusan will lead Minaris’ operations in Europe,” commented Dr. Kazuchika Furuishi, Corporate Officer and General Manager, Regenerative Medicine Business Sector of Showa Denko Materials Co., Ltd. “He is ideally suited to continue Minaris' growth path and to build a fully integrated global CDMO for cell and gene therapies.”

“I’m looking forward to guiding the company as CEO in such exciting times. The market for cell and gene therapy is rapidly evolving and with our recently announced expansion of the European facilities, we are well positioned to meet the industry’s demand,” said Dusan Kosijer.

He takes over the position from Dr. Christine Guenther. “I am very grateful for Christine’s outstanding work through the last 12 years, pioneering the field of cell and gene therapy and building a successful CDMO business,” said Dusan Kosijer. Dr. Guenther had a decisive role in leading the company from a start-up (then named apceth Biopharma GmbH) up to the transformative acquisition of the company by Showa Denko Materials Co., Ltd. (formerly named Hitachi Chemical Co., Ltd.) in 2019. She will remain a member of the company’s Board of Directors and will be pursuing new challenges in the field of drug development.

 

About Minaris Regenerative Medicine

Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. We offer our clients high value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with more than 20 years’ experience providing outstanding quality and reliability. Our facilities in the US, Europe, and Asia allow us to supply patients worldwide with life-changing therapies. Minaris Regenerative Medicine is wholly owned by Showa Denko Materials Co., Ltd.

For more information, please visit www.rm.minaris.com

 

Contact

Dr. Luc St-Onge

Global Head of Sales and Marketing

Minaris Regenerative Medicine GmbH

 

E-Mail: press@rm.minaris.de

Phone: +49 (0)89 700 9608-0

Please read the German press release here/Pressemitteilung auf Deutsch

Media Contact Info:

*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Soltuions (HCATS, formerly PCT or PCT Cell Therapy Services), apceth Biopharma GmBH are all now operating under the name Minaris Regenerative Medicine. Hitachi Chemical Co., Ltd. has been renamed Showa Denko Materials Co., Ltd.

Stay up to date
on the latest news